Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swiss biotech firm Actelion has shown that use of its drug Tracleer can decrease pulmonary vascular resistance and increase exercise capacity in patients suffering from Eisenmenger's syndrome.
Subscribe to our email newsletter
The so-called Breath-5 study evaluated the use of Tracleer (bosentan) in patients with Eisenmenger’s syndrome, a progressive heart condition that occurs in people who have a congenital heart defect or hole in the heart, resulting in the development of a severe form of pulmonary arterial hypertension (PAH). This syndrome cannot be treated by any conventional means, including surgery.
The multi-centre study is the first ever trial to show benefit in this very sick group of patients. The standard regime of Tracleer was used treating a total of 54 patients over 16 weeks.
The results show that patients with bosentan treatment demonstrate a decrease in pulmonary vascular resistance (PVR) and an improvement in exercise capacity without a worsening in oxygen saturation. Overall the bosentan safety and tolerability profile was comparable to that observed in previous placebo-controlled clinical trials in PAH with Tracleer.
Dr Michael Landzberg from Brigham and Womens Hospital, Boston and principal investigator for the study commented: “Eisenmenger’s syndrome is a field of high unmet medical need. It is remarkable that in this disease, which was believed to be characterized by irreversible vascular lesions, finally a drug has shown an improvement in exercise capacity. At the same time Tracleer was well tolerated.”